Galectin Therapeutics

Galectin Therapeutics has added Dr. Henry Brem as an independent member of its board of directors; Brem holds the Henry Brem Professorship of Neurosurgery at Johns Hopkins University and co-developed image-guided surgical techniques and local drug-delivery systems. The company is developing Belapectin to inhibit Galectin-3; the program for metabolic dysfunction-associated steatohepatitis with cirrhosis has FDA Fast Track status. The stock returned 97.5% last year but is down 23.6% year-to-date, and analysts point to a lack of profitability and short-term liabilities exceeding cash. » More on de.investing.com

Marc Rubin has resigned his mandate on the board of Galectin Therapeutics effective January 10; the company emphasizes the resignation was not due to disagreements over business operations. Galectin received written feedback from the FDA on Belapectin and plans a follow-up Type C meeting, with target patients for a registration study assessed as consistent, but key study-design questions still open. New biomarker analyses from the NAVIGATE study suggest antifibrotic effects of Belapectin and a lower rate of new varices. At the 2025 annual general meeting, all nominated directors were re-elected. » More on de.investing.com

Galectin Therapeutics stock fell about 33.6% in pre-market trading after the FDA provided written feedback instead of a face-to-face meeting on the Belapectin development program. The company plans another Type C meeting to clarify remaining key aspects of the study design for a registration‑relevant Phase 3 trial; there is agreement on the patient population. Galectin will present new biomarker data at the follow-up meeting and has meanwhile arranged an unsecured, convertible credit line of $10 million from chairman Richard E. Uihlein and extended maturities of existing receivables to June 30, 2027. » More on de.investing.com